Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients

The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following Taxotere based regimens.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Irofulven; Drug: Prednisone; Drug: Irofulven; Drug: Capecitabine; Drug: Mitoxantrone

Detailed Description

For every five patients randomized, two will receive treatment number 1 (irofulven + prednisone), two patients will receive treatment number 2 (irofulven + capecitabine (Xeloda®) + prednisone), and one patient will receive treatment number 3 (mitoxantrone + prednisone). This is not a blinded study, so both the patient and doctor will know which treatment has been assigned.

• Study Type: Interventional
• Enrollment (Actual): 135
• Phase: Phase 2

Contacts and Locations

Study Locations

• Brazil
  • Belo Horizonte, Brazil
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
• Canada
  • Alberta
    • Calgary, Alberta, Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada
  • Ontario
    • London, Ontario, Canada
  • Quebec
    • Montreal, Quebec, Canada
• Chile
  • Santiago, Chile
• Croatia
  • Zagreb, Croatia
• France
  • Avignon, France
  • Orleans, France
  • Paris, France
  • Saint-Brieuc, France
  • Saint-Gregoire, France
• Peru
  • Lima, Peru
• Romania
  • Bucharest, Romania
  • Cluj-Napoca, Romania
• Russian Federation
  • Arkhangelsk, Russian Federation
  • Chelyabinsk, Russian Federation
  • Moscow, Russian Federation
• United States
  • Arkansas
    • Hot Springs, Arkansas, United States
    • Jonesboro, Arkansas, United States
  • California
    • Greenbrae, California, United States
  • Colorado
    • Colorado Springs, Colorado, United States
  • Florida
    • Bonita Springs, Florida, United States
    • Bradenton, Florida, United States
    • Cape Coral, Florida, United States
    • Ft. Meyers, Florida, United States
    • Naples, Florida, United States
    • Port Charlotte, Florida, United States
    • Sarasota, Florida, United States
    • Venice, Florida, United States
  • Georgia
    • Atlanta, Georgia, United States
    • Augusta, Georgia, United States
    • Macon, Georgia, United States
    • Marietta, Georgia, United States
  • Illinois
    • Chicago, Illinois, United States
  • Minnesota
    • Minneapolis, Minnesota, United States
  • Montana
    • Billings, Montana, United States
  • New York
    • Albany, New York, United States
    • East Setauket, New York, United States
  • Ohio
    • Kettering, Ohio, United States
  • South Carolina
    • Greenville, South Carolina, United States
  • Tennessee
    • Nashville, Tennessee, United States
  • Texas
    • Dallas, Texas, United States
    • Ft. Worth, Texas, United States
    • Tyler, Texas, United States
  • Washington
    • Spokane, Washington, United States
  • Wisconsin
    • Marshfield, Wisconsin, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

To be included in the study, patients must meet the following criteria:

1. Cancer of the prostate confirmed by a biopsy sample.
2. 18 years of age or older.
3. Disease must have spread beyond the prostate as proven by chest x ray, abdominal and pelvic computed tomography (CT) scan, bone scan or clinical examination.
4. At least one prior hormonal treatment with documented disease progression during hormone therapy.
5. One previous line of chemotherapy that included Taxotere® (as monotherapy or in combination). This could be in addition to estramustine single agent therapy.
6. Disease progression during prior Taxotere-based therapy or within 3 months of discontinuing.
7. Recovered from any toxic effects of prior chemotherapy, radiotherapy and surgery.
8. Recovered from any toxic effects associated with other investigational drugs, if applicable.
9. Signed informed consent obtained prior to initiation of any study-specific procedures or treatment.

Exclusion Criteria:

Patients cannot participate in the study if any of the following apply:

1. Unable to use prednisone.
2. Prior treatment with irofulven, capecitabine (Xeloda), continuous/protracted infusion 5-FU (5-fluorouracil) (infusion duration greater than or equal to 24 hours), other fluoropyrimidines or mitoxantrone.
3. Ongoing treatment with a corticosteroid at a prednisone-equivalent dose > 10 mg/day.
4. More than 1 prior treatment with either 153Sm or 89Sr, or radioisotope treatment within 8 weeks prior to entering this study.
5. Initiation of treatment with bisphosphonate agents (e.g., pamidronate, etidronate) within 2 months of entering the study. Pre-existing treatment with bisphosphonate agents is to be continued during this study.
6. Treatment with warfarin and/or phenytoin within 14 days before entering this study or during the study period.

Please note: There are additional inclusion/exclusion criteria. The study center will determine if patients meet all of the criteria. If patients do not qualify for the trial, study personnel will explain the reasons. If patients do qualify, study personnel will explain the trial in detail and answer any questions. Patients can then decide if they wish to participate.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Irofulven + prednisone	Drug: Irofulven; Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.; Drug: Prednisone; Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.; Drug: Irofulven; Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
Experimental: 2; Irofulven + capecitabine + prednisone	Drug: Irofulven; Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.; Drug: Prednisone; Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.; Drug: Irofulven; Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.; Drug: Capecitabine; Subjects will receive oral capecitabine at a dose of 1000 mg/m^2 twice daily for 15 days every 28 days.
Active Comparator: 3; Mitoxantrone + prednisone	Drug: Prednisone; Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.; Drug: Mitoxantrone; Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m^2 per day, once every 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Time to progression: RECIST (Response Evaluation Criteria in Solid Tumors) criteria	Between randomization and study discontinuation or disease progression, whichever occurs later.
Time to progression: Prostate-specific antigen (PSA) evolution (Prostate-Specific Antigen Working Group Recommendations [PSAWGR criteria]).	Between randomization and study discontinuation or disease progression, whichever occurs later.

Secondary Outcome Measures

Outcome Measure	Time Frame
Efficacy: Overall survival; objective response rate and PSA response rate according to RECIST and PSAWGR criteria, respectively.	Between randomization and death.
Determine safety profile of each treatment arm: incidence and severity of adverse events (AEs), serious AEs, and laboratory abnormalities.	Between randomization until a minimum of 30 days after last dose of study drug; treatment-related AEs will be followed until resolution.
Assess pain response in patients with significant pain at baseline using Tannock criteria and McGill-Melzack Pain Questionnaire.	Seven days prior to randomization and prior to each new cycle of study drug administration.
Quality of life (QOL) as measured by the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI).	Between baseline and study drug discontinuation.

Collaborators and Investigators

• Sponsor: Eisai Inc.

Study record dates

Study Major Dates

• Study Start: June 1, 2004
• Primary Completion (Actual): January 1, 2006
• Study Completion (Actual): December 1, 2009

Study Registration Dates

• First Submitted: July 26, 2005
• First Submitted That Met QC Criteria: July 26, 2005
• First Posted (Estimate): July 28, 2005

Study Record Updates

• Last Update Posted (Estimate): January 18, 2016
• Last Update Submitted That Met QC Criteria: January 15, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: Docetaxel; Taxotere; Irofulven
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Capecitabine; Prednisone; Mitoxantrone; Irofulven
• Other Study ID Numbers: IROF-018